A vaccine given during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and transferring immunity through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly 50 per cent of newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the vaccine safeguards at-risk babies
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects roughly half of all newborns in their first few months of life. The virus can range from causing mild cold-like symptoms to triggering severe chest infections that leave babies struggling to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of serious RSV infections: “In babies with bad infections you can see their chest and lungs working hard, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening for good reason.”
The pregnancy vaccine operates by activating the mother’s immune system to generate protective antibodies, which are then transferred to the foetus through the placenta. This maternal immunity provides newborns with instant defence from the moment of birth, exactly when they are most vulnerable to RSV. The latest research demonstrates that protection reaches approximately 85% when the vaccine is administered at least four weeks before delivery. Even shorter intervals between vaccination and birth can still provide substantial defence, with evidence suggesting that a two-week gap is sufficient to shield babies born slightly early. Dr Watson recommends pregnant women to have the vaccine on schedule, whilst observing that protection remains possible even if given later in the third trimester.
- Nearly 85 per cent coverage when vaccinated four weeks before birth
- Antibodies from the mother passed through placenta protect newborns from day one
- Protection possible with two-week gap before premature birth
- Vaccination during third trimester still provides meaningful infant protection
Persuasive evidence from current research
The performance of the RSV vaccine administered during pregnancy has been established through a thorough investigation undertaken in England, analysing data from close to 300,000 babies born between September 2024 and March 2025. This accounts for approximately 90% of all births during that six-month period, providing strong and reliable evidence of the vaccine’s actual performance. The study’s conclusions have been supported by the UK Health Security Agency as showing “excellent protection” for newborns during their most critical early weeks. The scope of this study provides healthcare professionals and parents-to-be with assurance in the vaccine’s established performance across diverse populations and circumstances.
The results paint a striking picture of the vaccine’s ability to protect. More than 4,500 babies were treated in hospital with RSV throughout the study period, with the overwhelming majority being infants whose mothers did not receive the vaccination. This marked difference highlights the vaccine’s vital importance in reducing the risk of serious illness in newborns. The decrease in hospital admissions above 80 per cent represents a significant public health achievement, helping to prevent thousands of infants from experiencing the frightening and potentially life-threatening symptoms connected with severe RSV infection. These findings strengthen the importance of the vaccination programme launched in the UK in 2024.
Methodology and scope of study
The research examined birth and hospitalisation records from England over a six-month timeframe, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were in a position to determine clear comparisons of RSV infection levels and hospitalisations. The sizeable sample and comprehensive nature of the data collection ensured that findings were statistically significant and reflective of the wider population, rather than isolated cases or limited subgroups.
The study specifically tracked hospital admissions for RSV among infants born to mothers who had been given the vaccine at varying intervals before delivery. This allowed researchers to identify the shortest interval needed between vaccination and birth for optimal protection, as well as to determine whether protection continued to be effective with shorter intervals. The methodology measured practical outcomes rather than controlled laboratory conditions, providing practical evidence of how the vaccine performs when given across diverse clinical settings and patient circumstances throughout pregnancy’s final trimester.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Comprehending RSV and the dangers
Respiratory syncytial virus, typically known as RSV, is one of the leading causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their first few months of life, with severity varying dramatically from mild cold-like symptoms to serious, potentially fatal chest infections. More than 20,000 babies require serious hospital treatment for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during peak seasons.
The infection causes inflammation deep within the lungs and airways, making it perilously hard for affected infants to breathe and feed effectively. Parents commonly see their babies fighting for breath, their chests heaving as they work to get enough air into their weakened respiratory system. Whilst most newborns recover with supportive care, a modest yet notable proportion perish from RSV complications yearly, making prevention through vaccination a essential public health priority for protecting the youngest and most at-risk individuals in the population.
- RSV triggers inflammation in lungs, resulting in severe breathing difficulties in babies
- Nearly 50% of newborns acquire the infection during their first few months alive
- Symptoms vary between mild colds to life-threatening chest infections needing hospital treatment
- Over 20,000 UK infants need serious hospital treatment for RSV each year
- Small numbers of infants die from RSV related complications annually in the UK
Adoption rates and specialist advice
Since the RSV vaccine programme commenced in 2024, health officials have highlighted the significance of pregnant women getting their jab at the ideal time for maximum protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has underscored that timing matters greatly for guaranteeing newborns benefit from the most robust immunity from birth. Whilst the evidence indicates that vaccination performed at least four weeks prior to delivery offers approximately 85% protection, experts recommend women to get their vaccine as soon as feasible from 28 weeks of pregnancy onwards to increase the antibodies passed to their babies through the placenta.
The messaging from public health bodies stays clear: pregnant women should prioritise vaccination during their final three months, even if circumstances mean they cannot get vaccinated at the optimal time. Dr Watson has reassured pregnant women that protection remains still achievable with reduced timeframes between vaccination and birth, including even a fourteen-day window for those giving birth ahead of schedule. This flexible approach recognises the realities of pregnancy and childbirth whilst ensuring strong protection for vulnerable newborns during their earliest and most vulnerable period when RSV poses the greatest risk of serious illness.
Regional differences in immunisation
Whilst the RSV vaccine programme has been launched across England, uptake rates and deployment schedules have varied across various areas and NHS trusts. Some areas have achieved greater immunisation rates among eligible pregnant women, whilst others remain focused to increase awareness and access to the jab. These regional differences reflect differences across medical facilities, communication strategies, and community involvement initiatives, though the overall statistics shows robust and reliable protection regardless of geographical location.
- NHS trusts rolling out multiple messaging strategies to reach expectant mothers
- Geographic variations in vaccine uptake rates across England require targeted improvement
- Regional health providers modifying schemes to suit specific population needs
Real-world impact and parent viewpoints
The vaccine’s remarkable effectiveness translates into real advantages for families throughout the United Kingdom. With more than 20,000 babies admitted to hospital annually due to RSV prior to the introduction of this protective measure, the 80% reduction in admissions equates to thousands of infants protected against severe infection. Parents no more face the troubling prospect of watching their newborns gasping for air or struggle to eat, symptoms that characterise severe RSV infections. The vaccine has markedly changed the landscape of neonatal lung health, offering expectant mothers a active means to protect their most at-risk babies during those critical early months.
For families like that of Malachi, whose serious RSV infection caused devastating brain damage, the vaccine’s accessibility carries profound emotional significance. His mother’s promotion of the jab highlights the profound consequences that treatable infection can cause to young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story resonates powerfully with parents now offered protection. The knowledge that such significant complications—hospitalisation, oxygen dependency, neurological damage—are now largely preventable has offered substantial reassurance to women in pregnancy navigating their third trimester, transforming what was once an predictable seasonal threat into a controllable health concern.